TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease. The company now has multiple clinical trials underway at the Mayo Clinic in Rochester, MN, as well as an infectious disease program also completing pre-clinical testing at Mayo for a novel smallpox vaccine. In addition to our own sponsored clinical trials, we recently announced that a new grant-funded breast and ovarian cancer trial was started by Mayo using the same Folate Alpha receptor peptides to which we have the exclusive rights. Our development pipeline is extremely strong and provides us the opportunity to continue to expand on collaborations with leading institutions and corporations.